Skip to main content

Advertisement

Table 2 Change in the individual immunosignature between diagnosis and reoccurrance 1

From: The immunosignature of canine lymphoma: characterization and diagnostic application

     Portion of the signature decreasing by 3 months2 Portion of signature returning to pretreatment Levels at relapse3
Individual Type4 DFI (days)5 Peptides6 Number7 Percent8 Median fold change at day 90 Number Percent Median fold change vs day 0
247690 B 174 3 0 0 1.21 0 0 0.78
248661 B 280 5 1 20 0.85 0 0 0.59
251332 B 273 10 7 70 0.59 0 0 0.42
251661 B 119 71 65 92 0.42 5 7 0.37
252343 B 257 11 9 82 0.46 1 9 0.49
253509 B 270 7 7 100 0.45 0 0 0.20
256744 B 112 3 1 33 0.87 1 33 0.94
257195 B 333 4 3 75 0.69 1 25 0.45
219623 T 185 2 1 50 0.78 1 50 0.95
238300 T 167 5 4 80 0.54 0 0 0.49
243388 T 270 3 3 100 0.37 3 100 1.42
251702 T 71 6 0 0 1.37 0 0 1.40
  1. 1The individual signature is defined as the number of peptides uniquely recognized by each individual compared to other dogs in the study.
  2. 2The number of peptides in the individual immunosignature that decreased in normalized RFI greater than the minimum detectable fold change of 0.76.
  3. 3The number of peptides with a normalized RFI that returned to within the minimum detectable fold change of 0.76 to 1.3x of the values at diagnosis by the time they were clinically out of remission.
  4. 4Phenotype of the lymphoma, B cell or T cell.
  5. 5Time between initiation of treatment and being clinically defined as out of remission.
  6. 6The number of peptides comprising the individual immunsignature.
  7. 7The number of peptides comprising the individual immunsignature that decreased at three months.
  8. 8Percent of the individual immunosignature that decreased at three months.